Vortioxetine manufacturing process

US9353073B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9353073-B2
Application numberUS-201414767350-A
CountryUS
Kind codeB2
Filing dateFeb 20, 2014
Priority dateFeb 22, 2013
Publication dateMay 31, 2016
Grant dateMay 31, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A process for the manufacture of vortioxetine is provided in which a compound of formula I, formula I is reacted with optionally substituted piperazine and 2,4-dimethylthiophenol(ate) followed by de-cmplexation.

First claim

Opening claim text (preview).

The invention claimed is: 1. A process for the manufacture of vortioxetine or pharmaceutically acceptable salts thereof, which process comprises reacting a compound of formula I wherein each Hal independently represents fluoro or chloro; R′ represents H or R′ represents one or two moieties independently selected from CHO, COOH, COOR′″ or COONR′″ 2 , or R′ represents one to five moieties independently selected from C 1-6 -alkyl; R′″ independently represents H or C 1-6 -alkyl; and X − represents a non-coordinating and non-nucleophilic anion, with a piperazine of formula II wherein R represents H, and with a compound of formula III wherein R″ represents H or a cation, and an optional base in a solvent to obtain a compound of formula IV followed by a de-complexation step in which the optionally substituted cyclopentadienyliron is de-complexed to obtain 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine (vortioxetine). 2. The process according to claim 1 , wherein Hal represents chloro. 3. The process according to claim 1 , wherein R′ represents hydrogen. 4. The process according to claim 1 , wherein X − is selected from the group consisting of PF 6 − , AlCl 4 − , ClO 4 − , BF 4 − , [B[3,5-(CF 3 ) 2 C 6 H 3 ] 4 ] − , B(C 6 F 5 ) 4 − and Al(OC(CF 3 ) 3 ) 4 − . 5. The process according to claim 4 , wherein X − is PF 6 − . 6. The process according to claim 1 , wherein said solvent is selected from the group consisting of toluene, THF (tetrahydrofuran), MTBE (methyl tertiary-butyl ether), water, ethanol, 2-propanol, NMP (N-Methyl-2-pyrrolidone), DMF (dimethylformamide), MIBK (methylisobutyl ketone), TEA (triethyl amine), DIPEA (N,N-diisopropylethylamine), DCM (dichloromethane), ethylacetate, isopropylacetate and combinations of these. 7. The process according to claim 1 , wherein R″ represents H. 8. The process according to claim 1 , wherein said de-complexation step comprises photolysis. 9. The process according to claim 1 , wherein 1 equivalent of a compound of formula I is mixed with a compound of formula II (1-5 equivalents) and a compound of formula III (1-5 equivalents) in a solvent together with a base (more than 0.5 equivalent) to obtain a compound of formula IV followed by de-complexation to obtain 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. 10. The process according to claim 1 , wherein 1 equivalent of a compound of compound of formula I is mixed with a base (between 0.5 and 20 equivalents), piperazine (1-5 equivalents) and 2,4-dimethyl thiophenol (1-5 equivalents) in a solvent to obtain a compound of formula IV, followed by de-complexation to obtain 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. 11. The process according to claim 1 , wherein 1 equivalent of η 6 -1,2-dichlorobenzene-η 5 -cyclopentadienyliron(II) hexafluorophosphate is mixed with 1-5 equivalent base, 1-3 equivalents 2,4-dimethylthiophenol and 1-3 equivalents piperazine in a solvent at 10° C-50° C. to obtain the compound of the formula followed by de-complexation to obtain 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. 12. The process according to claim 1 , wherein the obtained 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine is reacted with a suitable acid to obtain the equivalent pharmaceutically acceptable salt.

Assignees

Inventors

Classifications

  • with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings · CPC title

  • Iron compounds · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9353073B2 cover?
A process for the manufacture of vortioxetine is provided in which a compound of formula I, formula I is reacted with optionally substituted piperazine and 2,4-dimethylthiophenol(ate) followed by de-cmplexation.
Who is the assignee on this patent?
Lundbeck & Co As H
What technology area does this patent fall under?
Primary CPC classification C07D295/096. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).